Navigation Links
Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
Date:1/18/2011

ter to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PLPRJHFKD.  A replay of the call will be available for two weeks following the event.

To access the live conference call via phone, dial 888-679-8037.  International callers may access the live call by dialing 617-213-4849.  The reference number to enter the call is 64749679.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers.  The reference number for the replay of the call is 58180972.

About Alexza Pharmaceuticals, Inc.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted the AZ-004 NDA in December 2009.  In October 2010, the Company received a CRL from the FDA, regarding its NDA
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
2. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
3. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
4. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
7. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
8. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
9. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
10. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
11. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the ... Healthcare Distribution Specialist, LLC ("HDS") are pleased to announce ... Vitamin & Sports Nutrition Expo to be held at ... Florida on July 15-17, 2012.  As part of the ...
... announced today the Clinical Laboratory Responsibility Pledge, a ... ethical business practices in the medication monitoring industry. ... adheres and to which the company challenges every ... adopt. (Logo: http://photos.prnewswire.com/prnh/20120203/LA47138LOGO ) ...
Cached Medicine Technology:Sunpeaks Ventures to Participate in ECRM Conference and Expo 2Sunpeaks Ventures to Participate in ECRM Conference and Expo 3Millennium Laboratories Announces Laboratory Responsibility Pledge 2Millennium Laboratories Announces Laboratory Responsibility Pledge 3
(Date:4/18/2014)... A group of scientists from the University of ... on Aging has found interesting new information in ... Parkinson,s disease (PD). , Published in the ... assessed cognitive function in depressed and non-depressed patients ... commonly used to treat motor symptoms of Parkinson,s ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... Expected to Achieve Strong Uptake in this ... from Decision ResourcesWALTHAM, Mass., April 30 ... research and advisory firms for pharmaceutical and ... Amgen/Wyeth/Takeda,s Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe,s Remicade, and Abbott/Eisai,s ...
... creates federal-state-local partnership to help fight domestic violence, ... $1.1 million U.S. Justice Dept. grant is fueling ... to help combat domestic violence and sexual assault ... Appellate Prosecutor,s office has hired two full-time prosecutors ...
... steroid to multiple sclerosis treatment shows promise in study ... steroid drug in combination with a multiple sclerosis (MS) ... using the MS drug alone, suggests a new study. ... relapsing-remitting MS, some patients were randomly selected to receive ...
... of the pancreas, invagination of the pancreas into the ... fistula, according to researchers at the Jefferson Pancreas, Biliary ... the Journal of the American College of Surgeons ... the gold standard for studies. , Removing the head ...
... 2008...sales up 266%, , ... Winston-Salem, ... today that it is expanding its corporate and satellite offices ... stabilization system, VerteLoc™. , , , , ,"We are essentially ...
... principles for Getting Health IT Right under the American ... the Markle Foundation hosts a forum to discuss the ... (IT) under the American Recovery and Reinvestment Act (ARRA). ... with government and policy experts to talk about how ...
Cached Medicine News:Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 3Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:VGI Announces Expansion to Meet Surgeon Demand for the VerteLoc™ Spine Stabilization System 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 3
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
The CRW system epitomizes simplicity, quality assurance, and versatility....
Used to negotiate tortuous vessels....
Hydrosteer wires are intended for use in the percutaneous introduction of catheters....
Medicine Products: